Citigroup
CGON icon

Citigroup’s CG Oncology CGON Stock Holding History

Citigroup’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.61M Buy
135,225
+121,029
+853% +$7.91M ﹤0.01% 1653
2026
Q1 		$961K Sell
14,196
-3,493
-20% -$198K ﹤0.01% 3140
2025
Q4 		$734K Sell
17,689
-18,682
-51% -$773K ﹤0.01% 3337
2025
Q3 		$1.47M Sell
36,371
-13,758
-27% -$400K ﹤0.01% 2918
2025
Q2 		$1.3M Sell
50,129
-45,753
-48% -$1.1M ﹤0.01% 3003
2025
Q1 		$2.35M Buy
95,882
+24,246
+34% +$682K ﹤0.01% 2560
2024
Q4 		$2.05M Buy
71,636
+36,430
+103% +$1.25M ﹤0.01% 2796
2024
Q3 		$1.33M Buy
35,206
+24,597
+232% +$862K ﹤0.01% 3025
2024
Q2 		$335K Buy
10,609
+6,325
+148% +$219K ﹤0.01% 3630
2024
Q1 		$188K Buy
+4,284
New +$175K ﹤0.01% 4048

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's CGON Position: Q2 2026 in Review

Citigroup increased its CG Oncology (CGON) stake by 853% in Q2 2026, buying an estimated $7.91M and bringing the position to 135,225 shares worth $9.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Citigroup first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Citigroup held 135,225 shares of CG Oncology worth $9.61M as of Q2 2026.
  • Citigroup bought 121,029 CG Oncology shares in Q2 2026, an estimated $7.91M.
  • CG Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1653 holding.
  • Citigroup first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.